Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Roche selects Cyprotex for drug discovery support

The Cyprotex group (LSE: CRX) today announces that it has entered into an agreement with Roche to provide drug discovery support.

Under the terms of the agreement, Cyprotex will provide experimental services that will enable Roche scientists to evaluate and optimise the absorption, distribution, metabolism and elimination (ADME) properties of potential drug candidates early in the drug discovery process.

Commenting on the agreement with Roche, Mark Egerton, CEO of Cyprotex, said: "We are extremely pleased to be working with Roche, a leading global pharmaceutical company. The fact that Roche selected Cyprotex after a rigorous due diligence process represents another validation step in the development of our business."

Philippe Coassolo, Head of Discovery-DMPK at Roche Basel, said: "We have selected Cyprotex to support our drug discovery projects as they clearly demonstrated that their science and technology platform in ADME testing has the potential to offer a close ongoing relationship between our two companies."

- Ends -

For further information:

Dr Mark Egerton, Chief Executive Officer

Cyprotex PLC
Tel: +44 (0) 1625 505 100

m.egerton@cyprotex.com
www.cyprotex.com

Media enquiries:

Henry Harrison-Topham/ Heather Salmond

Bankside Consultants Limited
Tel: +44 (0) 20 7444 4141
henry.ht@bankside.com
www.bankside.com

Notes to editors:

Cyprotex PLC - www.cyprotex.com
With facilities in Manchester, UK, and Research Triangle Park, North Carolina, Cyprotex is developing a technology platform to evaluate and optimise ADME/PK (pharmacokinetics), a key requirement in the discovery and development of successful drugs. Cyprotex's products and services are used by partners in order to improve the efficiency and effectiveness of their drug discovery processes and may be accessed as either 'fee for service' projects, risk-sharing initiatives or through licensing and technology transfer. Cyprotex aims to become the partner of choice to provide pharmaceutical and biotechnology companies with novel experimental and in silico ADME/PK technology and services.

Roche - www.roche.com
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-orientated healthcare groups in the fields of pharmaceuticals, diagnostics and vitamins. Roche's products and services address prevention, diagnosis and treatment of diseases, thus enhancing well being and quality of life. Roche has approximately 64,000 employees and sells its products in over 170 countries. Research at Roche focuses on significant unmet medical needs in the management of central nervous system, genitor-urinary tract, metabolic, inflammatory, bone, cancer, vascular and viral diseases.

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close